COVID, Pediatric Disorder
Conditions
Brief summary
In December 2019, an outbreak of pneumonia of unknown aetiology was first reported in the city of Wuhan, Hubei Province, People's Republic of China. Since then, a novel coronavirus, 2019 novel Coronavirus (2019-nCoV) has emerged as the most likely causative agent. To date, it has evolved into a pandemic involving over a million cases and thousands of deaths have been identified, including a high burden in countries like Italy, Spain, United Kingdom and the United States. This study aims to investigate the clinical epidemiology of 2019-novel coronavirus (2019-nCoV) pandemic in Asia.
Detailed description
A retrospective/prospective outbreak study of all suspect cases admitted to hospital since the beginning of the pandemic (December 2019). Clinical and epidemiological information will be extracted from medical databases for analysis.
Interventions
None listed
Sponsors
King Chulalongkorn Memorial Hospital
Ramathibodi Hospital
Post Graduate Institute of Medical Education and Research, Chandigarh
Rumah Sakit Anak dan Bunda Harapan Kita
National University Hospital, Singapore
St. Marianna University School of Medicine
Tokyo Metropolitan Children's Medical Center, Japan
Aichi Children's Health and Medical Center, Japan
RS H Adam Malik
Children's Hospital of Chongqing Medical University
Zhengzhou Children's Hospital, China
Universiti Kebangsaan Malaysia Medical Centre
Penang Hospital, Malaysia
Vicente Sotto Memorial Medical Center
Hyogo Prefectural Kobe Children's Hospital
Singapore Clinical Research Institute
KK Women's and Children's Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
* COVID-19 suspected cases (by whatever definition) * COVID-19 confirmed cases (based on PCR or serum specific IgM and IgG antibody of novel coronavirus; serum specific IgG of novel coronavirus from negative to positive or 4 times higher in convalescence than in acute phase) * \</=21years of age
Exclusion criteria
* COVID-19 suspected cases should not be SARSCoV-2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall severity of illness | 60days (or duration of hospital stay) | Mild, moderate, severe, critical |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory complications | 60days (or duration of hospital stay) | e.g. URTI, bronchiolitis, pneumonia, pneumothorax, effusion, pneumonitis, ARDS |
| Respiratory support | 60days (or duration of hospital stay) | e.g. oxygen, HFNC, NIV, mechanical ventilation |
| Other systems complications | 60days (or duration of hospital stay) | e.g. cardiovascular, renal, hepatic, neurological, haematological dysfunction |
| Mortality | 60days (or duration of hospital stay) | — |
| Length of hospital stay | 60days (or duration of hospital stay) | — |
Countries
China, India, Indonesia, Japan, Malaysia, Pakistan, Singapore
Outcome results
None listed